Did You Know?

Find answers to off-the-beaten path NSCLC trivia.

1 of 5

Bonnie J. Addario, founder and namesake of the Bonnie J. Addario Lung Cancer Foundation, was previously______

"CEO of an oil company"

"An elementary school teacher"

"A marathon runner"

Bonnie J. Addario was the CEO of an oil company. Click here to learn how she channeled her lung cancer diagnosis and the passing of Superman’s real-life wife more than a decade ago into one of the leading patient advocacy and support organizations for lung cancer patients and their loved ones.

2 of 5

The discovery of epidermal growth factor "EGF" in the 1960s would later win a Nobel Prize in Medicine and ultimately lead to the first biomarker-driven therapy for lung cancer. This discovery would not have been possible without____

"Whale oil"

"Tree bark"

"Salivary gland extract"

When medical researcher Stanley Cohen injected newborn mice with salivary gland extract, he observed that they opened their eyes and started forming teeth earlier than normal. He termed the substance in the extract epidermal growth factor ("EGF") because it could stimulate the multiplication of certain cells in the skin and cornea and was awarded a Nobel Prize in 1986 for his discovery. Read about it here.

Thanks to Stanley and his mice, mutated EGF receptors were eventually proposed as a target for anti-cancer treatment, and in 2003 the first EGFR inhibitor was approved by the FDA.¹

3 of 5

Biomarkers for lung cancer are mainly related to changes that happen in your____.

"Airway"

"Genes"

"Plasma"

Normal genes turn on and off in an orderly way to make protein messages tell cells what to do, like when to grow and multiply. Mutations or changes in some genes can turn a healthy cell into a cancerous one. Watch this video to learn more about this process and how scientists are using this information to gain a better understanding of the different types of NSCLC.

4 of 5

There are currently more than ___ ongoing clinical trials examining the role of known biomarkers in patients with NSCLC.²

"50"

"400"

"1500"

There are more than 400 clinical trials examining the role of biomarkers in NSCLC. Thanks to modern science, doctors now know that lung cancer is not just one disease. Even within the most common type – non-small cell lung cancer classified as adenocarcinoma – researchers have identified more than 15 genetic mutations that may cause cells to become cancerous, redefining our understanding of the disease.^3,4 With these discoveries, new treatments targeting these biomarkers can be developed and tested in real patients. Learn more about clinical trials or visit LungMatch from our partner organization Lung Cancer Alliance, a resource to help patients find a clinical trial based on his or her biomarker.

5 of 5

Doctors used to believe lung cancer was one disease. Today, more than __ biomarkers that drive lung cancer have been identified in NSCLC alone.

"15"

"5"

"27"

More than 15 biomarkers have been identified in NSCLC. Our understanding of lung cancer has evolved considerably in the 21st century. Today, doctors understand that there are two major types of lung cancer, the most common being non-small cell lung cancer. In NSCLC classified as adenocarcinoma, researchers have now identified more than 15 genetic mutations that may cause cells to become cancerous — redefining the disease and how it is treated.^3,4 Learn more about biomarkers and why it’s important to be tested.

¹Armour A, Watkins C. The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer. Eur Respir Rev. 2010;19(117):186-196.
²ClinicalTrials.gov. 420 studies found for: KRAS OR EGFR OR ALK OR PIK3CA OR HER2 OR BRAF OR ROS OR RET OR NRAS OR MET | lung cancer. https://clinicaltrials.gov/ct2/results?term=KRAS+OR+EGFR+OR+ALK+OR+PIK3CA+OR+HER2+OR+BRAF+OR+ROS+OR+RET+OR+NRAS+OR+MET+&type=Intr&rslt=Without&recr=Recruiting&age_v=&gndr=&cond=non+small+cell+lung+cancer+&intr=&titles=&outc=&spons=&lead=&id=&state1=&cntry1=&state2=&cntry2=&state3=&cntry3=&locn=&rcv_s. Accessed May 26, 2017. PLUS https://clinicaltrials.gov/ct2/results?term=KRAS+OR+EGFR+OR+ALK+OR+PIK3CA+OR+HER2+OR+BRAF+OR+ROS+OR+RET+OR+NRAS+OR+MET&type=Intr&rslt=Without&recr=Active%2C+not+recruiting&age_v=&gndr=&cond=non+small+cell+lung+cancer&intr=&titles=&outc=&spons=&lead=&id=&state1=&cntry1=&state2=&cntry2=&state3=&cntry3=&locn=&rcv_s=&rcv_e=&lup_s=&lup_e=. Accessed May 26, 2017. PLUS https://clinicaltrials.gov/ct2/results?term=KRAS+OR+EGFR+OR+ALK+OR+PIK3CA+OR+HER2+OR+BRAF+OR+ROS+OR+RET+OR+NRAS+OR+MET&type=Intr&rslt=Without&recrs=a&age_v=&gndr=&cond=non+small+cell+lung+cancer&intr=&titles=&outc=&spons=&lead=&id=&cntry1=&state1=&cntry2=&state2=&cntry3=&state3=&locn=&rcv_s=&rcv_e=&lup_s=&lup_e=. Accessed May 26, 2017.
³Kris MG, Johnson BE, Kwiatkowski DJ, et al. Identification of driver mutations in tumor specimens from 1000 patients with lung adenocarcinoma: the NCI’s Lung Cancer Mutation Consortium, (LCMC). J Clin Oncol. 2011;29(suppl; abstr CRA7506). Page 10. http://meetinglibrary.asco.org/content/81670-102. Accessed August 1, 2017.
⁴Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med. 2012;18(3):378-381. doi:10.1038/nm.2558.

Main new menu

Patient Stories Slider

Did You Know?

Find answers to off-the-beaten path NSCLC trivia.

Did You Know?

Find answers to off-the-beaten path NSCLC trivia.

Related Content